Body Mass Index and Outcomes in HR+/HER2− Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study
Cancers · 26.04.2026 · 18 (9) · 1379
DOI: 10.3390/cancers18091379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 26.04.2026. Verfasst von Larisa Maria Badau und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School in Medicine, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania.
Abstract (Originalsprache)
Background/Objectives: The prognostic and predictive role of BMI in patients with HR+/HER2− MBC remains controversial, particularly in the era of CDK4/6 inhibitors. This study aimed to evaluate the association between baseline BMI and clinical outcomes in patients treated with palbociclib in a real-world setting. Methods: We conducted a multicenter retrospective observational cohort study including 326 patients with HR+/HER2− MBC treated with palbociclib in combination with endocrine therapy across six oncology centers in Romania. Only patients who received palbociclib for at least three months were included. Patients were stratified according to BMI into
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School in Medicine, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
- Department of Oncology, ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
- Discipline of Hygiene, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
- "Pius Brinzeu" County Emergency Hospital, 300723 Timisoara, Romania.
- Department of Public Health and Sanitary Management, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
- Center for Studies in Preventive Medicine, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
ORCID-Profile: Larisa Maria Badau, Madalin-Marius Margan, Roxana Margan, Cristina Marinela Oprean
Förderung
- “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
Zitieren
APA
Badau, L. M., Epure, P., Margan, M. M., Margan, R., Ciocoiu, A. D., Oprean, C. M., & Vlaicu, B. (2026). Body Mass Index and Outcomes in HR+/HER2− Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study. Cancers, 18(9), 1379. https://doi.org/10.3390/cancers18091379
Vancouver
Badau LM, Epure P, Margan MM, Margan R, Ciocoiu AD, Oprean CM, et al. Body Mass Index and Outcomes in HR+/HER2− Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study. Cancers. 2026;18(9):1379. doi:10.3390/cancers18091379
BibTeX
@article{Badau2026,
author = {Badau, Larisa Maria and Epure, Paul and Margan, Madalin-Marius and Margan, Roxana and Ciocoiu, Andrei Dorin and Oprean, Cristina Marinela and Vlaicu, Brigitha},
title = {Body Mass Index and Outcomes in HR+/HER2− Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1379},
doi = {10.3390/cancers18091379}
}
EUVIMED